HIPEC Improves Long-Term Outcomes in Stage III Ovarian Cancer
Adding HIPEC to interval cytoreductive surgery improves long-term outcomes in stage III epithelial ovarian cancer, a phase 3 trial suggests.
Adding HIPEC to interval cytoreductive surgery improves long-term outcomes in stage III epithelial ovarian cancer, a phase 3 trial suggests.
Greater PFDE, PFNA, and PFUA associated with increased odds of previous melanoma.
Left ventricular ejection fraction data from the JAVELIN Ovarian 200 trial showed low cardiotoxicity in patients with ovarian cancer treated with avelumab, avelumab plus PLD, or PLD.
Screening can lead to earlier diagnosis of high-grade serous ovarian cancer, but this does not translate to a substantial improvement in survival, according to researchers.
A study determined oncology nurses are aware of biomarker testing and targeted therapy for ovarian cancer but seemed less aware of their specific details.
Bevacizumab can reduce the risk of progression in patients with ovarian cancer for about 1 year after treatment initiation, but discontinuing the drug increases the risk of progression, researchers found.
Increased odds ratios observed for employment as accountants; hairdressers, beauticians, and related workers; sewers and embroiderers.
Researchers sought to determine whether AI could improve oncology nursing for patients with cancer.
SGO, FWC, and GOG-F have released recommendations for how to treat patients with gynecologic cancers in light of current chemotherapy shortages.
Adding durvalumab to first-line therapy and adding durvalumab and olaparib to maintenance improves PFS in patients with ovarian cancer, phase 3 data suggest.